Titanium Device as a Permanent Replacement for a Human Heart  

Use of “BiVACOR Total Artificial Heart”, a titanium metal device has enabled the longest successful bridge to heart transplant lasting over three months. The patient was discharged from the hospital with the artificial heart still implanted. He received a donor heart transplant 100 days after implantation of the artificial device and is now recovering well. The patient thus survived for 100 days on the metal device that replaced his native heart. The device is based on a rotary centrifugal pump, uses a magnetically levitated impeller, has a single moving part, has no valves, and has a no-contact suspension system. It was developed as a bridge to heart transplantation but has the potential to serve as a permanent replacement for a human heart. If so, it would be a boon to heart failure patients unfit for heart transplantation as well as to many in the long queue of heart failure patients awaiting donor heart transplantation.  

A heart failure patient awaiting heart transplantation was implanted “BiVACOR Total Artificial Heart” as a bridge before a donor heart becomes available. This procedure for implantation of device was successfully performed by the clinical team of St Vincents Hospital in Sydney in late 2024. In early 2025, the patient was discharged from the hospital making him the first person in the world to leave a hospital with the “BiVACOR Total Artificial Heart”. After more than 100 days, which is the longest period for a patient with this implant, he successfully received a donor heart transplant in early March 2025. The patient is now recovering well.  

Late 2024:  “BiVACOR Total Artificial Heart (TAH)”, a titanium metal device implanted successfully in a male patient in his 40s suffering from severe heart failure, awaiting donor heart transplantation.  
Early February 2025:  The patient was discharged from the hospital making him the first person in the world to leave a hospital with the BiVACOR TAH implant. 
Early March 2025:  The patient survived on the titanium device before he received a donor heart transplant in early March 2025 and is now recovering well.  

The patient with severe heart failure thus survived on the implanted metal device for 100 days that performed the function of his native heart for the bridging period before a donor heart was transplanted.    

BiVACOR Total Artificial Heart is an implantable rotary biventricular blood pump. It uses a magnetically levitated impeller which is the only moving part. Changing the speed of the impeller generates “beats”. The device is not pulsatile and has no valves and has a no-contact suspension system. It only requires a battery pack to run.  

The BiVACOR TAH System replaces the function of diseased heart in the heart failure patients. It is intended to bridge the time to heart transplant. In the recent breakthrough, the device demonstrated a bridging period of over three months which suggests that it may have potential to serve as a permanent replacement for a human heart. If so, it would be a boon to heart failure patients unfit for heart transplantation as well as to many in the long queue of heart failure patients awaiting donor heart transplantation.  

Heart failure (also known as Congestive heart failure or Congestive cardiac failure CCF) is a condition when heart fails to pump adequate blood as required. It is a serious condition requiring intervention and may be caused due to many reasons including coronary heart diseaseheart inflammation, high blood pressure, cardiomyopathy, etc. Over 60 million people are affected by this condition worldwide. Many require heart transplantation however there is a long waiting queue due to limited availability of donor heart. An implantable effective device as a permanent replacement of human heart is very much need of the hour for heart failure patients.  

*** 

References:  

  1. The Texas Heart Institute. News – First Implanted by The Texas Heart Institute, BiVACOR TAH Keeps Australian Man Alive for 100 Days. Published 14 March 2025. Available at https://www.texasheart.org/bivacors-total-artificial-heart-first-implanted-at-the-texas-heart-institute-at-baylor-college-of-medicine-goes-100-days-while-australian-man-awaits-donor-heart/ 
  1. St Vincent’s Hospital. News – St Vincent’s Makes History with Australia’s First Total Artificial Heart Implant. Posted 12 March 2025. Available at https://www.svhs.org.au/newsroom/news/australia-first-total-artificial-heart-implant  
  1. Duke University Health System. Duke Implants Second-in-Human Total Artificial Heart. Published 5 November 2024. Available at https://physicians.dukehealth.org/articles/duke-implants-second-human-total-artificial-heart 
  1. Shah A.M., 2024. First successful implant of BiVACOR’s Total Artificial Heart. Artificial Organs. Published: 09 August 2024. DOI: https://doi.org/10.1111/aor.14844 
  1. BiVACOR. REPLACING HEARTS.RESTORING LIVES. Available at https://bivacor.com/  
  1. BiVACOR® Total Artificial Heart Early Feasibility Study https://clinicaltrials.gov/study/NCT06174103  

*** 

Latest

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Newsletter

Don't miss

A New Shape Discovered: Scutoid

A new geometrical shape has been discovered which enables...

Cost Effective Way to Convert Plants into Renewable Source of Energy

Scientists have shown a new technology in which bioengineered...

Galápagos Islands: What Sustains its Rich Ecosystem?

Situated about 600 miles west of coast of Ecuador...

Artificial Intelligence (AI) Systems Conduct Research in Chemistry Autonomously  

Scientists have successfully integrated latest AI tools (e.g. GPT-4)...

Voyager 1 resumes sending signal to Earth  

Voyager 1, the most distant man-made object in history,...
Umesh Prasad
Umesh Prasad
Umesh Prasad is a researcher-communicator who excels at synthesizing peer-reviewed primary studies into concise, insightful, and well-sourced public articles. A specialist in knowledge translation, he is driven by a mission to make science inclusive for non-English speaking audiences. Toward this goal, he founded “Scientific European,” this innovative, multilingual, open-access digital platform. By addressing a critical gap in global science dissemination, Prasad acts as a key knowledge curator whose work represents a sophisticated new era of scholarly journalism, bringing the latest research to the doorstep of common people in their native languages.

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such as Neuralink’s “Telepathy” implant involve establishing communication links between the brains of participants who have unmet medical needs due...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here